These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29096027)

  • 21. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.
    Zembles TN; Gaertner KM; Gutzeit MF; Willoughby RE
    Am J Health Syst Pharm; 2016 Mar; 73(6):405-8. PubMed ID: 26953285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palivizumab: The Effects of Prophylactic Immunization on the Occurrence of Infections Caused by the Respiratory Syncytial Virus.
    Raguz MJ; Brzica J; Grgic I
    Klin Padiatr; 2017 Sep; 229(5):281-285. PubMed ID: 28946159
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study.
    Chiu SN; Wang JN; Fu YC; Chung HT; Chang LY; Wu MH; Hua YC; Lin MT; Lu CW; Chen CA; Wu JM; Wang JK
    J Pediatr; 2018 Apr; 195():108-114.e1. PubMed ID: 29395174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of palivizumab in children with childhood interstitial lung disease: The French experience.
    Drummond D; Thumerelle C; Reix P; Fayon M; Epaud R; Clement A; Mahloul M; Habouria D; Delacourt C; Hadchouel A
    Pediatr Pulmonol; 2016 Jul; 51(7):688-95. PubMed ID: 26636747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
    Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates.
    Gortner L
    Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.
    Meissner HC; Rennels MB; Pickering LK; Hall CB
    Pediatr Infect Dis J; 2004 Mar; 23(3):284-5. PubMed ID: 15014320
    [No Abstract]   [Full Text] [Related]  

  • 28. Antimicrobial Stewardship.
    Cunha CB
    R I Med J (2013); 2018 Jun; 101(5):16-17. PubMed ID: 29857598
    [No Abstract]   [Full Text] [Related]  

  • 29. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease.
    Walpert AS; Thomas ID; Lowe MC; Seckeler MD
    Congenit Heart Dis; 2018 May; 13(3):428-431. PubMed ID: 29436781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The end of antibiotics in the management of uncomplicated acute diverticulitis.
    Slim K; Joris J; Beyer-Berjot L
    J Visc Surg; 2019 Oct; 156(5):373-375. PubMed ID: 31699337
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus.
    Blake SM; Tanaka D; Bendz LM; Staebler S; Brandon D
    Adv Neonatal Care; 2017 Aug; 17(4):292-298. PubMed ID: 27926583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate of palivizumab administration in accordance with current recommendations among hospitalized children.
    Moynihan JA; Kim TY; Young T; Checchia PA
    J Pediatr Health Care; 2004; 18(5):224-7. PubMed ID: 15337916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [National antibiotic stewardship policy: advocating a new strategy].
    Roger PM; Blanc V; Keita-Perse O; Lieutier-Colas F
    Med Mal Infect; 2014 Dec; 44(11-12):489-90. PubMed ID: 25455076
    [No Abstract]   [Full Text] [Related]  

  • 34. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
    Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory syncytial virus (RSV) infection in children with medical complexity.
    Lim A; Butt ML; Dix J; Elliott L; Paes B
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
    Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
    Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A standardized guideline for antibiotic prophylaxis in surgical neonates
    Laituri C; Arnold MA
    Semin Pediatr Surg; 2019 Feb; 28(1):53-56. PubMed ID: 30824135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.